Mirum Pharmaceuticals Provides AZURE Clinical Program Update for brelovitug in Chronic Hepatitis Delta Virus
Mirum Pharmaceuticals, Inc. - common stock (MIRM)
Last mirum pharmaceuticals, inc. - common stock earnings: 3/12 04:02 pm
Check Earnings Report
Company Research
Source: Business Wire
- Phase 3 AZURE-1 enrollment complete- Phase 3 AZURE-4 screening complete- Topline AZURE-1 and AZURE-4 results expected in 2H 2026- AZURE-1 and AZURE-4 to form the basis of Mirum’s U.S. BLA Submission FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced completion of enrollment in the Phase 3 AZURE-1 study and completion of screening in the Phase 3 AZURE-4 study, both evaluating brelovitug for the treatment of chronic hepatitis delta virus (HDV). Achievement of these milestones confirms the expected timing of topline 24-week data in the second half of 2026. AZURE-1 and AZURE-4 together will form the basis of Mirum’s U.S. BLA submission for brelovitug, which has received Breakthrough Therapy designation from the FDA for the treatment of chronic HDV infection.Brelovitug is being developed for HDV, the most severe form of viral hepatitis, and a disease with no approved therapies in the U.S. HDV occurs in peop
Show less
Read more
Impact Snapshot
Event Time:
MIRM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MIRM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MIRM alerts
High impacting Mirum Pharmaceuticals, Inc. - common stock news events
Weekly update
A roundup of the hottest topics
MIRM
News
- Mirum Pharmaceuticals Provides AZURE Clinical Program Update for brelovitug in Chronic Hepatitis Delta Virus [Yahoo! Finance]Yahoo! Finance
- Mirum Pharmaceuticals (MIRM) was given a new $126.00 price target by Evercore Inc.MarketBeat
- A Look At Mirum Pharmaceuticals (MIRM) Valuation After Volatile Trading On Common Stock Offering News [Yahoo! Finance]Yahoo! Finance
- Mirum Pharmaceuticals (MIRM) had its price target raised by TD Cowen from $115.00 to $117.00. They now have a "buy" rating on the stock.MarketBeat
- Mirum Pharmaceuticals (MIRM) had its "outperform" rating reaffirmed by Leerink Partners.MarketBeat
MIRM
Earnings
- 2/25/26 - Miss
MIRM
Sec Filings
- 2/25/26 - Form S-3ASR
- 2/25/26 - Form S-8
- 2/25/26 - Form 10-K
- MIRM's page on the SEC website